V ascular calcification, a type of ectopic soft tissue mineralization, increases the risk of cardiovascular mortality. Arterial wall mineralization is estimated to be present in the vast majority of patients affected by cardiovascular disease (CVD). 1 In particular, patients with end-stage renal disease have extensive medial and intimal calcification that is associated with a highly significant increase in cardiovascular mortality as compared with the general population. 2 It is now estimated that >15% of the population of the United States have chronic kidney disease (2010 US Renal Data System Annual Data Report, http://www.usrds.org/). Patients with type II diabetes mellitus are an additional population affected by elevated vascular calcification. 3 Given the dramatic rise in diabetes mellitus and metabolic syndrome in the United States, increased frequencies of vascular calcification and CVD are to be expected in the coming decades.
In the aorta, intimal and medial calcification promotes congestive heart failure by compromising vessel compliance and elasticity. Intimal calcification is positively correlated with atherosclerotic plaque burden, 4, 5 increased risk of myocardial infarction, 6, 7 plaque instability, 8, 9 and stroke, 10 and is an independent risk factor for cardiovascular mortality in the general population. 11 In human lesions, the process leading to vascular calcification seems to follow an osteochondrogenic pathway analogous to endochondral bone formation. In mouse lesions, vascular calcification is often accompanied by the appearance of cartilaginous metaplasia that subsequently mineralizes. 12, 13 Recent in vitro and in vivo studies indicate that vascular calcification is a highly regulated process involving smooth muscle cell (SMC) osteochondrogenic differentiation. [14] [15] [16] [17] What factors initiate vascular calcification? Strong evidence points to a role for oxidative stress that accompanies dyslipidemia and inflammation. 3 These factors also seem to be major regulators of bone morphogenetic proteins that are well-established regulators of SMC mineralization. 12, 18 Several additional factors have been identified to regulate and exacerbate osteochondrogenic gene expression and vascular SMC mineralization, and thus contribute to the acceleration of CVD. For example, macrophages and T-lymphocytes infiltrating the atherosclerotic lesion produce proinflammatory cytokines and other regulators of calcification that may induce SMC osteochondrogenic differentiation. 19, 20 Functional studies in vitro, as well as in vivo, indicate that osteoprotegerin (OPG) is a major regulator of bone remodeling by blocking receptor activator NF-κB ligand (RANKL) binding to its own cell surface receptor RANK, resulting in the inhibition of RANKL-dependent osteoclast formation. 21 More recently, OPG has been hypothesized to modulate vascular functions; however, its role in mediating atherosclerosis is controversial. Epidemiological data in CVD patients indicate that OPG serum levels are associated with several inflammatory markers, MI events, and calcium scores, suggesting that OPG may be causative for CVD. An opposite interpretation is that the rise in OPG levels may be an adaptive response to curb the harmful effects of RANKL and Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), the other known ligands for OPG. [22] [23] [24] [25] [26] Indeed, experimental data in animal models strongly suggest that OPG is a vascular protective factor. OPG delivery to apolipoprotein E (ApoE) −/− mice has been shown to induce matrix deposition, accumulation of SMCs in the plaque, and SMC proliferation, suggesting that OPG promotes features of plaque stabilization. 27, 28 Furthermore, OPG delivery has been shown to decrease plaque and aortic valve calcification. 23, 29 Despite showing that OPG delivery ameliorates some features of vascular disease, there were no effects on atherosclerotic lesion size. We have previously reported that OPG deficiency in ApoE −/− mice led to increased vascular calcification and lesion size, suggesting that endogenous OPG may also regulate atherosclerosis progression. 22 Furthermore, we recently demonstrated that the OPG ligand RANKL exacerbates macrophage-dependent SMC mineralization by inducing secretion of TNF-α and interleukin (IL)-6 in macrophages. 30 However, it is still unknown whether OPG regulation of inflammation or whether the direct effects of OPG on vessel wall cells mechanistically explain its vascular protective effects.
Based on this knowledge, we hypothesized that reconstitution of ApoE 
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

OPG Is Expressed by Different Vascular Cell Types In Vivo
Immunohistochemistry was used to determine the expression of OPG in the atherosclerotic vessel wall. Innominate arteries of 46-week-old ApoE −/− OPG +/+ mice were stained for OPG. As shown in Figure 1A and 1D, OPG was present in the lesion and the medial layer. Immunohistochemistry of adjacent sections with the macrophage marker, Mac2, and the SMC marker, smooth muscle α-actin, showed colocalization of these cells with OPG staining (Figure 1B and 1E) . From this analysis, it is also evident that most Mac2-positive cells express OPG, but only a subset of SMCs and chondrocyte-like cells expresses OPG, possibly indicating a specific response to the changing environment in the media during disease progression. OPG is not expressed in quiescent SMCs of nondiseased vessels (not shown).
Bone Marrow-and Vessel Wall-Derived OPG Is Sufficient to Delay Lesion Progression in the Innominate Artery
We have previously shown that lack of OPG in ApoE −/− mice led to increased lesion size. 22 However, the mechanism and Figure 2C and 2D). Quantification of lesion size showed that OPG −/− → ApoE −/− OPG −/− lesions were significantly larger that of all the other transplants that had similar lesion sizes ( Figure 2E ). We have also analyzed the lesion size in the aortic sinus. We found that OPG −/− → ApoE −/− OPG +/+ developed significantly smaller lesions than that of OPG −/− → ApoE −/− OPG -/-mice, thus confirming the findings in the innominate artery. Furthermore, we found no difference in lesion size when OPG +/+ marrow was transplanted into either genotype ( Figure III in the online-only Data Supplement). However, we noted that the disease progressed at a faster rate in the aortic sinus. This may explain why the observed differences were less dramatic than in the innominate artery. 
Cholesterol, Triglyceride, and Serum Cytokine Analysis
To determine whether there were possible systemic differences between the transplants, we measured total plasma cholesterol and total plasma triglycerides levels at termination (Table I in The increase in smooth muscle-α actin staining was associated with an increased frequency of thicker fibrous caps. There were no differences in the area of smooth muscle-α staining in the medial layer in any of the groups ( Figure 3K ).
Bone Marrow-and Vessel Wall-Derived OPG Inhibits Vascular Calcification
Medial and plaque-associated calcification was also evaluated in the innominate artery by Alizarin Red staining ( Figure 4A-D Figure 4E -G). Taken together with the effects on lesion size and composition, these results suggest that either BM-or vessel wall-derived OPG contributes to limit lesion expansion, complexity, and calcification.
Effect of Bone Marrow Transplantation on Bone Homeostasis
OPG is a well-established modulator of bone homeostasis, and OPG null mice are severely osteoporotic. 22, 31 To determine whether OPG +/+ → ApoE −/− OPG −/− and OPG −/− → ApoE −/− OPG −/− mice had altered trabecular bone morphology compared with the control transplants, we used micro computed tomography analysis of tibias from the different groups. Tissue volume (TV) was unchanged across groups, indicating that endocortical bone cell function in the metaphysis did not vary across groups ( Figure 5A ). We found that 
OPG Null Bone Marrow-Derived Cells Enhance SMC Calcification
A large proportion of circulation-derived cells populating the atherosclerotic lesion are macrophages and macrophagederived foam cells. As shown in Figure 1D , OPG was expressed by macrophages and foam cells in the lesion. In addition, OPG was secreted by macrophages differentiated in vitro from the BM ( Figure 6A ). 30 We found that in the presence of osteogenic conditions (2.6 mM phosphate), ApoE Figure 6B ). We also found that ApoE −/− OPG −/− macrophages secreted higher levels of the proinflammatory and promineralizing cytokines TNF-α and IL-6 ( Figure 6C and 6D) . To further explore whether macrophage-derived IL-6 and TNF-α may regulate known calcification mediators in SMCs, we performed coculture experiments in which IL-6 and TNF-α activities were inhibited by specific neutralizing antibodies. As shown in Figure 6E and 6F, we observed a reduction in heat shock protein (HSP70) and bone morphogenetic protein-2 mRNA levels. HSP70 has been shown to be induced by IL-6 and bone morphogenetic protein-2 by TNF-α. 3, 32 Phosphorylation of bone morphogenetic protein-2 downstream mediator SMAD1/5/8 was also reduced under these conditions ( Figure 6G ). We further performed RNA expression studies on 22-week-old aortas and determined that TNF-α and IL-6 are elevated in the ApoE 
Discussion
In the present study, we report that ApoE to reduce lesion progression. In vitro studies indicated that BM cell-derived OPG was sufficient to reduce SMC calcification.
The role of OPG and its ligands in the process of atherosclerosis and vascular calcification is a debate in the CVD field. Epidemiological data associate elevated serum OPG levels with several aspects of CVD, suggesting that OPG may be a causative factor. An alternate interpretation is that the rise of OPG in the serum may be an adaptive response. [22] [23] [24] [25] [26] Indeed, experimental data in animal models suggest that OPG is a vascular protective factor. Mouse studies addressing the role of exogenous OPG in atherosclerosis have analyzed various characteristics of the disease in a variety of models. The overall conclusion was that exogenous OPG promoted features of plaque stabilization and inhibited vascular calcification, supporting a vasculoprotective role for OPG. 23, [27] [28] [29] However, despite showing that OPG ameliorates some aspects of vascular disease, these studies also showed no effect of exogenously delivered OPG on atherosclerotic lesion size. In contrast, our studies using mice deficient in OPG show that its deficiency promotes lesion development and vascular calcification. 22 The reason why delivery of OPG has a less robust effect than lack of endogenous OPG is not clear. One possibility is that the OPG formulation and the duration of the treatment with exogenous OPG may account for the disparate observations. For example, in several studies, OPG was delivered at relatively low concentrations and for only 10-12 weeks. 27, 28 Furthermore, the majority of the studies used human OPG. 23, 29 In our studies, we examined 40-and 60-week-old mice when lesions are well developed and with a high degree of complexity. Another possible explanation is that the genetic deletion early in life is necessary to promote lesion progression.
In human plaques and media OPG, RANKL, and TRAIL are found associated with calcium deposits, suggesting an active local role for these factors in the process of vascular calcification. 36, 37 Because in our previous study we did not determine which cell type(s) was affected or produced OPG in the vessel wall, 22 we performed BM transplant experiments. The results of these new experiments strongly indicate that vessel wall-and BM-derived OPG reduces lesion size. The mice totally deficient of OPG, OPG −/− → ApoE
, had the largest and most complex lesions when compared with the other transplants where OPG was either expressed by vessel wall-derived or marrow-derived cells or both. When OPG was present in either compartment, the lesions tended to be smaller, macrophage/foam cell rich, with fewer SMCs and chondrocyte-like cells, and reduced proteoglycans and collagen, thus resembling early lesions. To our knowledge, this is the first evidence that vessel wall-derived or marrow-derived OPG can affect lesion size and progression.
Analysis of serum cholesterol at termination revealed no differences between the groups; however, triglycerides were significantly lower in the OPG −/− → ApoE −/− OPG −/− mice with a similar trend in the OPG +/+ → ApoE −/− OPG −/− mice. Absence of OPG may result in additional free and active RANKL and TRAIL. Interestingly, TRAIL negatively regulates adipogenesis. 38 Furthermore, ApoE −/− mice deficient for TRAIL have increased triglycerides and upregulation of genes modulating adipogenesis. 39 We also determined the serum levels for several cytokines and chemokines. Of the 20 factors analyzed, the only 2 factors showing statistically significant differences between the groups were the chemokine CXCL1 and cytokine IL-13, CXCL1 has also been shown to play a role in the recruitment of monocytes/macrophages into the atherosclerotic lesions of ApoE −/− and LDLR −/− mice. 41, 42 At this point, it is not clear why, in our system, serum CXCL1 was the lowest in the group with the largest lesions. IL-13 is a recognized antiinflammatory and atheroprotective cytokine. Cardilo-Reis et al 43 have recently shown that IL-13 modulates plaque composition by skewing macrophage phenotype. In agreement with these findings, we observe the highest IL-13 in the group with the smallest lesions. Interestingly, IL-13 has been shown to induce OPG in endothelial cells and osteoblasts 44 ; however, whether OPG also regulates IL-13 is not known.
OPG has been shown to modulate vascular calcification in the presence as well as in the absence of hyperlipidemia.
Indeed, Bucay et al 45 first showed that lack of OPG led to arterial calcification of a third of the mice. Furthermore, reintroduction of OPG either pharmacologically or by transgenic overexpression rescued the vascular calcification phenotype. 46 In the atherosclerotic background, we and others have shown that inhibition of OPG led to intimal calcification. 22, 23 Our latest transplant studies confirm those observations and extend them to show that vessel wall-derived or marrowderived OPG was sufficient to inhibit plaque and medial calcification, strongly arguing for a local paracrine/autocrine role of this molecule.
It has been shown that hyperlipidemia and oxLDL, besides inducing vascular calcification, also suppress bone formation and bone anabolic responses to PTH. 47 Thus, bone health is intimately coupled with vascular health and calcification, indicating that local, paracrine, or autocrine effects as well as systemic endocrine factors regulate the 2 systems. Indeed, chronic kidney disease patients suffer from metabolic bone disorder and extensive vascular calcification. 47 OPG is a well-established bone homeostasis factor because of its interaction with the osteoclast differentiation factor RANKL. In the bone, OPG and RANKL are produced predominantly by osteoblasts, act in a paracrine fashion to modulate osteoclast activity, and are regulated by parathyroid hormone and other bone-modulating factors/ hormones. 48 As a consequence, OPG null mice are severely osteoporotic because of unabated RANKL-dependent osteoclast activity. 22, 31, 45 Thus, in our studies, it was necessary to exclude the possibility that bone-derived endocrine factors rather than direct autocrine/paracrine effects of OPG on the vasculature were responsible for the observed anti-atherosclerosis phenotype. Our experimental design allowed us to dissect the bone phenotype from the vascular phenotype. The data showing rescue of atherosclerosis but not of osteoporosis in ApoE −/− OPG −/− mice by OPG+/+ marrow strongly argue for a vessel wall autocrine/paracrine and not a systemic endocrine role of OPG in the process of atherosclerosis and vascular calcification.
To help explain the in vivo observations, we performed in vitro assays to elucidate the relationship between SMCs, BM-derived macrophages, and mesenchymal stem cells in relation to vascular calcification. Strikingly, OPG −/− macrophages and mesenchymal stem cells strongly enhanced SMC calcification when compared with OPG +/+ cells, suggesting a paracrine role for OPG. Mechanistically, it is possible that the OPG produced by the marrow-derived cells inhibits the calcification process by interacting with procalcific OPG ligands. Indeed, RANKL is thought to be an inducer of vascular calcification in some circumstances. 49 To this end, we have recently determined that in the absence of OPG, RANK/RANKL signaling is a potent inducer of calcification (Callegari et al, submitted). We have also recently shown that RANKL stimulates macrophage production of TNF-α and IL-6, which in turn enhance SMC calcification. 30 Indeed, in this study, we found that OPG −/− macrophages produced more TNF-α and IL-6 than OPG +/+ macrophages. These factors also regulated expression of procalcific molecules in SMCs when in coculture with OPG −/− macrophages. We also found increased expression of TNF-α and IL-6 in aortas of ApoE −/− OPG −/− compared with ApoE −/− OPG +/+ mice. Taken together, these data suggest that a combination of OPG-direct and OPG-indirect pathways may contribute to the observed enhancement of SMC calcification. TNF-α and IL-6 have both been implicated in the induction of SMC mineralization and atherosclerosis progression. 20, 32 In conclusion, with this study, we show that expression of OPG in the vessel wall by a variety of cell types is beneficial because it reduces lesion size and progression and strongly inhibits calcium deposition. Importantly, our data strongly indicate that local production of OPG rather than systemic elevation drives the process. Finally, despite the established connection between the vasculature and the skeletal system, macrophage and other marrow-derived and vessel wallderived OPG does not affect bone homeostasis. Thus, methods to safely deliver this molecule to the vasculature may aid in the prevention and therapy of atherosclerosis and vascular calcification.
